Wolverine Asset Management’s NovoCure NVCR Stock Holding History

Wolverine Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-14,800	Closed	-$1.09M	–	2021
2022 Q4	$1.09M	Buy	+14,800	New	+$1.11M	0.01%	719
2018 Q3	–	Sell	-50,000	Closed	-$1.56M	–	1598
2018 Q2	$1.56M	Hold	50,000	–	–	0.02%	621
2018 Q1	$1.09M	Buy	+50,000	New	+$1.08M	0.01%	731

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Wolverine Asset Management's NVCR Position: Q4 2025 in Review

Wolverine Asset Management sold out of NovoCure (NVCR) in Q4 2025, closing a stake of 102 shares — an estimated $1.32K sold.

Wolverine Asset Management first reported a position in NVCR in Q1 2020 and held it in 12 quarters. The position peaked at $308K in Q1 2020. 239 funds tracked by Wall St. Rank hold NVCR as of Q4 2025.

Wolverine Asset Management reported no remaining NovoCure position as of Q4 2025 after selling out during the quarter.
Wolverine Asset Management sold 102 NovoCure shares in Q4 2025, an estimated $1.32K.
Wolverine Asset Management first reported a position in NovoCure in Q1 2020 and held it in 12 quarters.
Wolverine Asset Management's NovoCure position peaked at $308K in Q1 2020.
239 funds tracked by Wall St. Rank held NovoCure as of Q4 2025.

Based on Wolverine Asset Management's 13F filing for Q4 2025, filed 2 Feb 2026.